CN1020944C
(zh)
*
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
US6515117B2
(en)
*
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
FR2809310B1
(fr)
*
|
2000-05-26 |
2004-02-13 |
Centre Nat Rech Scient |
Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
|
ATE474572T1
(de)
|
2000-11-30 |
2010-08-15 |
Novodermix Internat Ltd |
Heilung von wunden
|
SI1368349T1
(sl)
*
|
2001-02-24 |
2007-06-30 |
Boehringer Ingelheim Pharma |
Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
|
US6936590B2
(en)
*
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
ATE423559T1
(de)
*
|
2001-04-04 |
2009-03-15 |
Ortho Mcneil Janssen Pharm |
Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
|
EP1385856B1
(en)
*
|
2001-04-11 |
2006-02-22 |
Bristol-Myers Squibb Company |
Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
|
US20030087843A1
(en)
*
|
2001-09-05 |
2003-05-08 |
Washburn William N. |
O-pyrazole glucoside SGLT2 inhibitors and method of use
|
TWI254635B
(en)
*
|
2002-08-05 |
2006-05-11 |
Yamanouchi Pharma Co Ltd |
Azulene derivative and salt thereof
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
WO2004031203A1
(ja)
|
2002-10-04 |
2004-04-15 |
Kissei Pharmaceutical Co., Ltd. |
ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
|
DE10258007B4
(de)
*
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
JP2006516257A
(ja)
*
|
2003-01-03 |
2006-06-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
C−アリールグルコシドsglt2阻害剤の製造法
|
EP1457206A1
(en)
*
|
2003-03-13 |
2004-09-15 |
Fournier Laboratories Ireland Limited |
Combined use of a fibrate and orlistat for the treatment of obesity
|
NZ542399A
(en)
|
2003-03-14 |
2009-01-31 |
Astellas Pharma Inc |
C-glycoside derivatives and salts thereof
|
JP2004300102A
(ja)
*
|
2003-03-31 |
2004-10-28 |
Kissei Pharmaceut Co Ltd |
縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
|
WO2005011592A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted indazole-o-glucosides
|
AU2004261660A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted fused heterocyclic C-glycosides
|
US8785403B2
(en)
*
|
2003-08-01 |
2014-07-22 |
Mitsubishi Tanabe Pharma Corporation |
Glucopyranoside compound
|
AR048282A1
(es)
*
|
2003-08-01 |
2006-04-19 |
Janssen Pharmaceutica Nv |
Indol- o - glucosidos sustituidos
|
CA2549022A1
(en)
*
|
2003-08-01 |
2005-02-10 |
Janssen Pharmaceutica N.V. |
Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
|
EP1651658B2
(en)
|
2003-08-01 |
2020-08-12 |
Mitsubishi Tanabe Pharma Corporation |
Novel compounds having inhibitory activity against sodium-dependant transporter
|
US7371759B2
(en)
*
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7420059B2
(en)
*
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
WO2005085265A1
(ja)
*
|
2004-03-04 |
2005-09-15 |
Kissei Pharmaceutical Co., Ltd. |
縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途
|
CN103450129B
(zh)
|
2004-03-16 |
2015-08-12 |
贝林格尔.英格海姆国际有限公司 |
吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
|
EP1750862B1
(en)
|
2004-06-04 |
2011-01-05 |
Teva Pharmaceutical Industries Ltd. |
Pharmaceutical composition containing irbesartan
|
US7393836B2
(en)
*
|
2004-07-06 |
2008-07-01 |
Boehringer Ingelheim International Gmbh |
D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
DE102004034690A1
(de)
*
|
2004-07-17 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
TW200606129A
(en)
*
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
JP2008508213A
(ja)
*
|
2004-07-27 |
2008-03-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法
|
AR051446A1
(es)
*
|
2004-09-23 |
2007-01-17 |
Bristol Myers Squibb Co |
Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
|
JP5046370B2
(ja)
*
|
2004-09-29 |
2012-10-10 |
キッセイ薬品工業株式会社 |
1−(β−D−グリコピラノシル)−3−置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
|
DE102004048388A1
(de)
|
2004-10-01 |
2006-04-06 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
JP4944034B2
(ja)
*
|
2004-10-13 |
2012-05-30 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Ptp1b発現のアンチセンス調節
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
DE602005009745D1
(de)
*
|
2004-12-16 |
2008-10-23 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
TWI365186B
(en)
*
|
2005-01-31 |
2012-06-01 |
Mitsubishi Tanabe Pharma Corp |
Indole derivatives
|
AR053329A1
(es)
*
|
2005-01-31 |
2007-05-02 |
Tanabe Seiyaku Co |
Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
|
US7238702B2
(en)
*
|
2005-02-10 |
2007-07-03 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5HT modulators
|
EP1856082B1
(en)
*
|
2005-02-23 |
2009-10-14 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors
|
ES2338041T3
(es)
*
|
2005-04-15 |
2010-05-03 |
Boehringer Ingelheim International Gmbh |
Derivados de (heteroariloxi-bencil)-benceno sustituidos con glucopiranosilo en calidad de inhibidores de sglt.
|
UA91546C2
(uk)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
US7723309B2
(en)
*
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
WO2007000445A1
(en)
*
|
2005-06-29 |
2007-01-04 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
TW200726755A
(en)
*
|
2005-07-07 |
2007-07-16 |
Astellas Pharma Inc |
A crystalline choline salt of an azulene derivative
|
EP1910390B1
(en)
*
|
2005-07-27 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
|
JP2009502959A
(ja)
*
|
2005-07-28 |
2009-01-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−1h−ピリド[4,3,b]インドール
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7795436B2
(en)
*
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
DE602006017566D1
(de)
*
|
2005-08-30 |
2010-11-25 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
JP5345846B2
(ja)
*
|
2005-09-08 |
2013-11-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
1−クロロ−4−(β−D−グルコピラノス−1−イル)−2−(4−エチニル−ベンジル)−ベンゼンの結晶形態、その製造方法及び薬剤製造のためのそれらの使用
|
AR056195A1
(es)
*
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
JP5094416B2
(ja)
*
|
2005-12-28 |
2012-12-12 |
武田薬品工業株式会社 |
糖尿病治療剤
|
EA200801773A1
(ru)
|
2006-02-15 |
2009-02-27 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Глюкопиранозилзамещенные производные бензонитрила, фармацевтические композиции, содержащие такие соединения, их применение и способ их получения
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
CA2810295C
(en)
|
2006-05-04 |
2017-11-14 |
Boehringer Ingelheim International Gmbh |
A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
US20090176717A1
(en)
*
|
2006-06-01 |
2009-07-09 |
Glycomimetics, Inc. |
Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
US7919598B2
(en)
|
2006-06-28 |
2011-04-05 |
Bristol-Myers Squibb Company |
Crystal structures of SGLT2 inhibitors and processes for preparing same
|
US7795291B2
(en)
|
2006-07-07 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
|
TWI418556B
(zh)
*
|
2006-07-27 |
2013-12-11 |
Mitsubishi Tanabe Pharma Corp |
吲哚衍生物
|
TWI403516B
(zh)
|
2006-07-27 |
2013-08-01 |
Chugai Pharmaceutical Co Ltd |
To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
|
TWI432446B
(zh)
|
2006-07-27 |
2014-04-01 |
Chugai Pharmaceutical Co Ltd |
稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
PL2097102T3
(pl)
*
|
2006-09-07 |
2012-10-31 |
Glaxosmithkline Biologicals Sa |
Szczepionka skojarzona o zmniejszonej ilości antygenu wirusa polio
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
US20080194575A1
(en)
*
|
2006-10-04 |
2008-08-14 |
Naiara Beraza |
Treatment for non-alcoholic-steatohepatitis
|
JPWO2008044762A1
(ja)
|
2006-10-13 |
2010-02-18 |
中外製薬株式会社 |
チオグルコーススピロケタール誘導体、およびその糖尿病治療薬としての使用
|
JP2010507629A
(ja)
|
2006-10-27 |
2010-03-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
4−(β−D−グルコピラノス−1−イル)−1−メチル−2−[4−((S)−テトラヒドロフラン−3−イルオキシ)−ベンジル]−ベンゼンの結晶形、その製造方法及び医薬品を製造するための使用
|
UY30730A1
(es)
*
|
2006-12-04 |
2008-07-03 |
Mitsubishi Tanabe Pharma Corp |
Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
|
NZ577391A
(en)
*
|
2006-12-04 |
2011-11-25 |
Janssen Pharmaceutica Nv |
Thienyl-containing glycopyranosyl derivatives as antidiabetics
|
MX2009005935A
(es)
|
2006-12-06 |
2009-06-30 |
Smithkline Beecham Corp |
Compuestos biciclicos y su uso como anti-diabeticos.
|
US8198464B2
(en)
|
2006-12-21 |
2012-06-12 |
Astellas Pharma Inc. |
Method for producing C-glycoside derivative and intermediate for synthesis thereof
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
WO2008109591A1
(en)
*
|
2007-03-08 |
2008-09-12 |
Lexicon Pharmaceuticals, Inc. |
Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
|
AR065809A1
(es)
|
2007-03-22 |
2009-07-01 |
Bristol Myers Squibb Co |
Formulaciones farmaceuticas que contienen un inhibidor sglt2
|
AU2014201239B2
(en)
*
|
2007-03-22 |
2016-03-10 |
Astrazeneca Ab |
Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate
|
TW200904454A
(en)
*
|
2007-03-22 |
2009-02-01 |
Bristol Myers Squibb Co |
Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
UA107175C2
(uk)
*
|
2007-07-26 |
2014-12-10 |
|
Спосіб і сполука, призначені для одержання інгібіторів контранспортера натрій-глюкози 2 типу, варіанти
|
PE20090603A1
(es)
*
|
2007-08-16 |
2009-06-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
|
PE20090938A1
(es)
*
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
KR101610005B1
(ko)
*
|
2007-08-17 |
2016-04-08 |
베링거 인겔하임 인터내셔날 게엠베하 |
Fab 관련 질환의 치료에 사용하기 위한 푸린 유도체
|
SI2187742T1
(en)
*
|
2007-08-23 |
2018-02-28 |
Theracos Sub, Llc |
DERIVATS (2S, 3R, 4R, 5S, 6R) -2- (4-CHLORO-3-BENZYLPHENYL) -6- (HYDROXYMETYL) TETRAHYDRO-2H-PIRAN-3,4,5-TRIOL FOR THE USE IN DIABETES TREATMENT
|
SI2200606T1
(sl)
*
|
2007-09-10 |
2017-12-29 |
Janssen Pharmaceutica N.V. |
Postopek za pripravo spojin, uporabnih kot inhibitorjev SGLT
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
WO2009068617A1
(en)
*
|
2007-11-30 |
2009-06-04 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo (3, 4-d) pyrimidin-4-one derivatives and their use as pde9a modulators for the teatment of cns disorders
|
UA101004C2
(en)
|
2007-12-13 |
2013-02-25 |
Теракос, Инк. |
Derivatives of benzylphenylcyclohexane and use thereof
|
CN104387354A
(zh)
*
|
2007-12-27 |
2015-03-04 |
阿斯利康公司 |
Sglt2 抑制剂的晶体结构及其制备方法
|
CL2008003653A1
(es)
|
2008-01-17 |
2010-03-05 |
Mitsubishi Tanabe Pharma Corp |
Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
|
KR101516677B1
(ko)
*
|
2008-01-31 |
2015-05-04 |
고토부키 세이야쿠 가부시키가이샤 |
지방성 간 질환의 치료용 의약 조성물
|
CN101503399B
(zh)
*
|
2008-02-04 |
2012-06-27 |
白鹭医药技术(上海)有限公司 |
C-芳基葡萄糖苷sglt2抑制剂
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
PE20140960A1
(es)
*
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
JP5820269B2
(ja)
|
2008-05-22 |
2015-11-24 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物
|
US8603989B2
(en)
*
|
2008-05-22 |
2013-12-10 |
Bristol-Myers Squibb Company |
Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
|
US8518895B2
(en)
|
2008-05-22 |
2013-08-27 |
Bristol-Myers Squibb Company |
Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
|
PE20100156A1
(es)
*
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US9061060B2
(en)
*
|
2008-07-15 |
2015-06-23 |
Theracos Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
ES2624828T3
(es)
|
2008-07-16 |
2017-07-17 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
KR101657960B1
(ko)
*
|
2008-08-15 |
2016-09-20 |
베링거 인겔하임 인터내셔날 게엠베하 |
Fab-관련 질환의 치료에 사용하기 위한 푸린 유도체
|
ES2599330T3
(es)
|
2008-08-22 |
2017-02-01 |
Theracos Sub, Llc |
Proceso para la preparación de inhibidores de SGLT2
|
WO2010023594A1
(en)
*
|
2008-08-28 |
2010-03-04 |
Pfizer Inc. |
Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
|
KR20110063447A
(ko)
|
2008-09-08 |
2011-06-10 |
베링거 인겔하임 인터내셔날 게엠베하 |
피라졸로피리미딘 및 cns 장애의 치료를 위한 이들의 용도
|
EP2344195A2
(en)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Combination therapy for the treatment of diabetes and related conditions
|
AU2009294606A1
(en)
*
|
2008-09-19 |
2010-03-25 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
WO2010045656A2
(en)
*
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Novel sglt2 inhibitor dosage forms
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
KR20170028452A
(ko)
|
2009-02-13 |
2017-03-13 |
베링거 인겔하임 인터내셔날 게엠베하 |
1형 당뇨병, 2형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 sglt2 억제제
|
EA024072B1
(ru)
|
2009-02-13 |
2016-08-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Фармацевтическая дозированная форма, включающая производное глюкопиранозилдифенилметана, и применения для улучшения гликемического контроля у пациентов
|
AU2010212867B2
(en)
|
2009-02-13 |
2013-05-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof
|
MX2011008839A
(es)
*
|
2009-02-23 |
2011-09-28 |
Taisho Pharmaceutical Co Ltd |
Compuestos de 4-isopropilfenilglucitol como inhibidores de transportador de glucosa dependiente de sodio 1.
|
EP2226076A1
(de)
|
2009-02-25 |
2010-09-08 |
Henning Vollert |
Pflanzlicher Extrakt zur Prophylaxe und Behandlung von hyperglykämischen Erkrankungen
|
AU2010230290B2
(en)
|
2009-03-31 |
2013-03-14 |
Boehringer Ingelheim International Gmbh |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators
|
EP2435033A1
(en)
*
|
2009-05-27 |
2012-04-04 |
Bristol-Myers Squibb Company |
Methods for treating type 2 diabetes in patients resistant to previous treatment with other anti-diabetic drugs employing an sglt2 inhibitor and compositions thereof
|
US20110009347A1
(en)
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
KR101532412B1
(ko)
|
2009-07-10 |
2015-06-29 |
얀센 파마슈티카 엔.브이. |
1-(β-D-글루코피라노실)-4-메틸-3-(5-(4-플루오로페닐)-2-티에닐메틸) 벤젠의 결정화 방법
|
TW201118099A
(en)
*
|
2009-08-12 |
2011-06-01 |
Boehringer Ingelheim Int |
New compounds for the treatment of CNS disorders
|
KR101813025B1
(ko)
*
|
2009-09-30 |
2017-12-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실치환된 벤질벤젠 유도체의 제조방법
|
NZ598318A
(en)
*
|
2009-09-30 |
2014-02-28 |
Boehringer Ingelheim Int |
Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
ME02634B
(me)
*
|
2009-10-14 |
2017-06-20 |
Janssen Pharmaceutica Nv |
Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
|
US8163704B2
(en)
*
|
2009-10-20 |
2012-04-24 |
Novartis Ag |
Glycoside derivatives and uses thereof
|
KR101426180B1
(ko)
|
2009-11-02 |
2014-07-31 |
화이자 인코포레이티드 |
디옥사-비시클로[3.2.1]옥탄-2,3,4-트리올 유도체
|
PL2498759T3
(pl)
|
2009-11-13 |
2019-03-29 |
Astrazeneca Ab |
Formulacje tabletek o natychmiastowym uwalnianiu
|
SI2498758T1
(sl)
|
2009-11-13 |
2018-10-30 |
Astrazeneca Ab |
Formulacije dvoplastnih tablet
|
AU2010317842A1
(en)
|
2009-11-16 |
2012-07-12 |
Mellitech |
[1,5]-diazocin derivatives
|
CA2782179C
(en)
|
2009-11-27 |
2020-06-23 |
Boehringer Ingelheim International Gmbh |
Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
|
AR079438A1
(es)
|
2009-12-09 |
2012-01-25 |
Panacea Biotec Ltd |
Derivados de azucar, composiciones farmaceuticas y sus usos
|
CN102134226B
(zh)
*
|
2010-01-26 |
2013-06-12 |
天津药物研究院 |
一类苯基c-葡萄糖苷衍生物、其制备方法和用途
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
EP2552442A1
(en)
*
|
2010-03-30 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
ES2935300T3
(es)
|
2010-05-05 |
2023-03-03 |
Boehringer Ingelheim Int |
Combiterapia
|
SG185525A1
(en)
|
2010-05-11 |
2012-12-28 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
|
US20130052266A1
(en)
|
2010-05-11 |
2013-02-28 |
Mitsubishi Tanabe Pharma Corporation |
TABLETS CONTAINING A 1-(beta-D-GLUCOPYRANOSYL)-3-(PHENYLTHIENYLMETHYL)BENZENE COMPOUND
|
WO2011153712A1
(en)
|
2010-06-12 |
2011-12-15 |
Theracos, Inc. |
Crystalline form of benzylbenzene sglt2 inhibitor
|
ES2953123T3
(es)
|
2010-06-24 |
2023-11-08 |
Boehringer Ingelheim Int |
Terapia para la diabetes
|
EP2603511B1
(en)
|
2010-08-12 |
2017-03-15 |
Boehringer Ingelheim International GmbH |
6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
JP5837072B2
(ja)
|
2010-09-03 |
2015-12-24 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
水溶性抗酸化剤を使用する製剤
|
WO2012037034A1
(en)
|
2010-09-14 |
2012-03-22 |
Glycomimetics, Inc. |
E-selectin antagonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
CN102453026A
(zh)
|
2010-10-27 |
2012-05-16 |
上海艾力斯医药科技有限公司 |
C-芳基葡糖苷衍生物、制备方法及其应用
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TWI631963B
(zh)
*
|
2011-01-05 |
2018-08-11 |
雷西肯製藥股份有限公司 |
包含鈉-葡萄糖共同輸送體1與2之抑制劑的組合物與應用方法
|
WO2012106303A1
(en)
|
2011-02-01 |
2012-08-09 |
Bristol-Myers Squibb Company |
Pharmaceutical formulations including an amine compound
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
US8980829B2
(en)
|
2011-02-18 |
2015-03-17 |
Shanghai Yingli Science And Technology Co., Ltd |
Aryl glycoside compound, preparation method and use thereof
|
CN102167715B
(zh)
*
|
2011-03-07 |
2013-04-24 |
上海惠斯生物科技有限公司 |
一种钠-葡萄糖协同运转蛋白-2原料药的共晶制备方法
|
AR085689A1
(es)
|
2011-03-07 |
2013-10-23 |
Boehringer Ingelheim Int |
Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
|
AU2012241897C1
(en)
|
2011-04-13 |
2017-05-11 |
Janssen Pharmaceutica Nv |
Process for the preparation of compounds useful as inhibitors of SGLT2
|
EP2703396B1
(en)
*
|
2011-04-25 |
2016-06-22 |
Beijing Prelude Pharm. Sci.& Tech. Co., Ltd. |
Inhibitor of sodium-dependent glucose transport protein and preparation method therefor and use thereof
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
|
CN103649033B
(zh)
*
|
2011-05-26 |
2016-02-24 |
Tf化学公司 |
芳基、杂芳基、o-芳基和o-杂芳基碳环糖家族
|
ES2448398T3
(es)
|
2011-06-03 |
2014-03-13 |
Ratiopharm Gmbh |
Composición farmacéutica que comprende dapagliflozina y ciclodextrina
|
CA2837627A1
(en)
|
2011-06-03 |
2012-12-06 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
CA2837232A1
(en)
*
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
JP5875678B2
(ja)
|
2011-06-25 |
2016-03-02 |
山東軒竹医薬科技有限公司 |
C−グルコシド誘導体
|
US20130035298A1
(en)
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
EP2731947B1
(en)
|
2011-07-15 |
2019-01-16 |
Boehringer Ingelheim International GmbH |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
US9018249B2
(en)
|
2011-09-13 |
2015-04-28 |
Panacea Biotec Limited |
SGLT inhibitors
|
JP2014532639A
(ja)
*
|
2011-10-31 |
2014-12-08 |
サイノファーム タイワン,リミティド |
Sglt2阻害剤の結晶および非結晶形態
|
EP2597090A1
(en)
*
|
2011-11-28 |
2013-05-29 |
Sandoz AG |
Crystalline dapagliflozin hydrate
|
DK2794626T6
(da)
|
2011-12-22 |
2020-08-24 |
Glycomimetics Inc |
E-selectin-antagonistforbindelser
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US9193751B2
(en)
|
2012-04-10 |
2015-11-24 |
Theracos, Inc. |
Process for the preparation of benzylbenzene SGLT2 inhibitors
|
EP3685839A1
(en)
|
2012-05-14 |
2020-07-29 |
Boehringer Ingelheim International GmbH |
Linagliptin for use in the treatment of albuminuria and kidney related diseases
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2013178064A1
(zh)
*
|
2012-05-29 |
2013-12-05 |
广东东阳光药业有限公司 |
吡喃葡萄糖基衍生物、其制备方法及其在医药上的应用
|
EP2679229B1
(de)
|
2012-06-30 |
2019-02-27 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
IN2015DN01975A
(no)
*
|
2012-08-30 |
2015-08-14 |
Taisho Pharmaceutical Co Ltd |
|
ES2668045T3
(es)
|
2012-12-07 |
2018-05-16 |
Glycomimetics, Inc. |
Compuestos, composiciones y métodos que usan antagonistas de la E-selectina para la movilización de las células hematopoyéticas
|
CN103910769B
(zh)
|
2012-12-31 |
2018-10-02 |
上海璎黎药业有限公司 |
葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
US8652527B1
(en)
|
2013-03-13 |
2014-02-18 |
Upsher-Smith Laboratories, Inc |
Extended-release topiramate capsules
|
WO2014159151A1
(en)
|
2013-03-14 |
2014-10-02 |
Msd International Gmbh |
Methods for preparing sglt2 inhibitors
|
US9101545B2
(en)
|
2013-03-15 |
2015-08-11 |
Upsher-Smith Laboratories, Inc. |
Extended-release topiramate capsules
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
DK2981269T3
(da)
|
2013-04-04 |
2023-10-23 |
Boehringer Ingelheim Vetmedica Gmbh |
Behandling af stofskifteforstyrrelser hos hestedyr
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CN105377266A
(zh)
|
2013-04-18 |
2016-03-02 |
勃林格殷格翰国际有限公司 |
药物组合物、治疗方法及其用途
|
WO2014178040A1
(en)
|
2013-04-29 |
2014-11-06 |
Mapi Pharma Ltd. |
Co-crystals of dapagliflozin
|
RS65632B1
(sr)
|
2013-06-05 |
2024-07-31 |
Bausch Health Ireland Ltd |
Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
|
WO2015040571A1
(en)
|
2013-09-23 |
2015-03-26 |
Ranbaxy Laboratories Limited |
Process for the preparation of dapagliflozin
|
EP3049397A1
(en)
*
|
2013-09-27 |
2016-08-03 |
Sun Pharmaceutical Industries Ltd |
Process for the purification of dapagliflozin
|
EP2895490B1
(en)
|
2013-09-27 |
2016-10-19 |
Sunshine Lake Pharma Co., Ltd. |
Glucopyranosyl derivatives and their uses in medicine
|
WO2015051484A1
(en)
|
2013-10-12 |
2015-04-16 |
Theracos, Inc. |
Preparation of hydroxy-benzylbenzene derivatives
|
EP3063116A1
(en)
*
|
2013-10-31 |
2016-09-07 |
Sun Pharmaceutical Industries Ltd |
Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
|
EP3862003B1
(en)
|
2013-12-17 |
2023-10-25 |
Boehringer Ingelheim Vetmedica GmbH |
An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals
|
WO2015101916A1
(en)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Process for the preparation of empagliflozin
|
US9315438B2
(en)
|
2014-01-03 |
2016-04-19 |
Xuanzhu Pharma Co., Ltd |
Optically pure benzyl-4-chlorophenyl-C-glucoside derivative
|
CN106349201B
(zh)
*
|
2014-01-03 |
2018-09-18 |
山东轩竹医药科技有限公司 |
光学纯的苄基-4-氯苯基的c-糖苷衍生物
|
CN103739581B
(zh)
*
|
2014-01-23 |
2016-11-23 |
中国药科大学 |
C-芳基葡萄糖苷sglt2抑制剂
|
CN105960242A
(zh)
|
2014-01-23 |
2016-09-21 |
勃林格殷格翰动物保健有限公司 |
犬科动物中代谢紊乱的治疗
|
CN104829572B
(zh)
*
|
2014-02-10 |
2019-01-04 |
江苏豪森药业集团有限公司 |
达格列净新晶型及其制备方法
|
IN2014MU00626A
(no)
*
|
2014-02-21 |
2015-09-25 |
Cadila Healthcare Ltd |
|
WO2015128853A1
(en)
|
2014-02-28 |
2015-09-03 |
Sun Pharmaceutical Industries Limited |
Dapagliflozin compositions
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
US20170029398A1
(en)
*
|
2014-03-06 |
2017-02-02 |
Srinivasan Thirumalai Rajan |
Process for the preparation of (1s)-1,5-anhydro-1-c-{4-chloro-3-4[(4-ethoxyphenyl)methyl]phenyl]-glucitol and its solvate thereof
|
CA2943704C
(en)
|
2014-04-01 |
2023-03-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
CN105001213B
(zh)
|
2014-04-14 |
2020-08-28 |
上海迪诺医药科技有限公司 |
C-芳基糖苷衍生物、其药物组合物、制备方法及应用
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
US20170135981A1
(en)
*
|
2014-05-16 |
2017-05-18 |
Astrazeneca Ab |
Method for Suppressing Glucagon Secretion of an SGLT2 Inhibitor
|
US9676741B1
(en)
|
2014-06-23 |
2017-06-13 |
Sun Pharmaceutical Industries Limited |
Co-crystal of dapagliflozin with citric acid
|
FI3197429T3
(fi)
|
2014-09-25 |
2024-06-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Yhdistelmähoito sglt2:n estäjillä ja dopamiiniagonisteilla aineenvaihduntahäiriöiden ehkäisemiseksi hevoseläimissä
|
AU2015323779B2
(en)
|
2014-09-25 |
2018-08-09 |
Astrazeneca Ab |
Combination of an omega-3 fatty acid and an SGLT-2 inhibitor for treating diseases of the liver
|
CN104327027B
(zh)
*
|
2014-10-14 |
2017-04-05 |
中国药科大学 |
一类新型c‑芳基葡萄糖苷sglt2抑制剂
|
CN104478839A
(zh)
*
|
2014-11-24 |
2015-04-01 |
苏州乔纳森新材料科技有限公司 |
一种达格列净的合成方法
|
CN104496952B
(zh)
*
|
2014-11-28 |
2017-04-19 |
深圳翰宇药业股份有限公司 |
一种达格列净的合成方法
|
HUE045542T2
(hu)
|
2014-12-03 |
2019-12-30 |
Glycomimetics Inc |
E-szelektinek és CXCR4 kemokin receptorok heterobifunkcionális inhibitorai
|
CN105753910A
(zh)
*
|
2014-12-16 |
2016-07-13 |
康普药业股份有限公司 |
一种卡格列净中间体的制备方法
|
CN104529970A
(zh)
*
|
2015-01-08 |
2015-04-22 |
江苏联环药业股份有限公司 |
制备达格列净的方法
|
CN104530149A
(zh)
*
|
2015-01-14 |
2015-04-22 |
佛山市赛维斯医药科技有限公司 |
卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478968A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478957A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
|
CN104478959A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
|
CN104478966A
(zh)
*
|
2015-01-14 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
含苯胺噻唑基的o-半乳糖苷衍生物、其制备方法和用途
|
CN104478963A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一种含腈基苯s-葡萄糖苷结构的化合物及其用途
|
CN104478965A
(zh)
*
|
2015-01-15 |
2015-04-01 |
佛山市赛维斯医药科技有限公司 |
一类烷氧基苯基s-葡萄糖苷衍生物、其制备方法和用途
|
CN104497070A
(zh)
*
|
2015-01-15 |
2015-04-08 |
佛山市赛维斯医药科技有限公司 |
一种含三氟甲基苯s-葡萄糖苷结构的化合物和用途
|
WO2016128995A1
(en)
|
2015-02-09 |
2016-08-18 |
Indoco Remedies Limited |
Process for the preparation of sglt inhibitor compounds
|
EA201791982A1
(ru)
|
2015-03-09 |
2020-02-17 |
Интекрин Терапьютикс, Инк. |
Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
|
WO2016161995A1
(en)
|
2015-04-08 |
2016-10-13 |
Zentiva, K.S. |
Solid forms of amorphous dapagliflozin
|
WO2016178148A1
(en)
*
|
2015-05-05 |
2016-11-10 |
Glenmark Pharmaceuticals Limited |
Process for preparation of dapagliflozin
|
CN106317068A
(zh)
*
|
2015-06-23 |
2017-01-11 |
中国科学院上海药物研究所 |
一种c,o-螺环芳基糖苷类化合物及其制备和应用
|
CN104961715B
(zh)
*
|
2015-07-10 |
2017-08-22 |
浙江美诺华药物化学有限公司 |
一种达格列净的制备方法
|
US10428053B2
(en)
|
2015-09-15 |
2019-10-01 |
Laurus Labs Limited |
Co-crystals of SGLT2 inhibitors, process for their preparation and pharmaceutical compositions thereof
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
CZ2015729A3
(cs)
|
2015-10-13 |
2017-04-26 |
Zentiva, K.S. |
Příprava intermediátů pro syntézu Canagliflozinu a Dapagliflozinu
|
JP2018530592A
(ja)
|
2015-10-15 |
2018-10-18 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
代謝性ミオパチーの治療に使用するためのsglt−2阻害剤
|
CN105218329B
(zh)
*
|
2015-10-15 |
2017-05-03 |
上海应用技术学院 |
一种列净类似物中间体及其制备方法
|
US9845303B2
(en)
|
2015-10-19 |
2017-12-19 |
Cadila Healthcare Limited |
Process for the preparation of dapagliflozin
|
CN106892929B
(zh)
*
|
2015-12-17 |
2020-01-14 |
上海艾力斯医药科技有限公司 |
螺缩酮衍生物及其制备方法和应用
|
CN105693669A
(zh)
*
|
2015-12-28 |
2016-06-22 |
南昌大学 |
一种抗糖尿病化合物及其制备方法和用途
|
DK3404033T3
(da)
*
|
2016-01-04 |
2020-11-02 |
Jeil Pharmaceutical Co Ltd |
C-glukosidderivat med kondenseret phenylring eller farmaceutisk acceptabelt salt deraf, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende dette
|
WO2017118945A1
(en)
|
2016-01-08 |
2017-07-13 |
Lupin Limited |
Premix of dapagliflozin and process for the preparation thereof
|
US11045485B2
(en)
|
2016-01-22 |
2021-06-29 |
Glycomimetics, Inc. |
Glycomimetic inhibitors of PA-IL and PA-IIL lectins
|
US9834533B2
(en)
*
|
2016-02-19 |
2017-12-05 |
Scinopharm Taiwan, Ltd. |
Process for preparing SGLT2 inhibitors and intermediates thereof
|
WO2017151708A1
(en)
|
2016-03-02 |
2017-09-08 |
Glycomimetics, Inc. |
Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
|
BR112018069782A2
(pt)
|
2016-03-31 |
2019-01-29 |
Lupin Ltd |
composição farmacêutica de dapagliflozina
|
CN107304194A
(zh)
*
|
2016-04-20 |
2017-10-31 |
扬子江药业集团上海海尼药业有限公司 |
制备达格列净的方法
|
JP7007300B2
(ja)
*
|
2016-05-24 |
2022-01-24 |
江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 |
ダパグリフロジンの新規な結晶形並びにその製造方法および用途
|
WO2017203229A1
(en)
|
2016-05-27 |
2017-11-30 |
Cipla Limited |
Dapagliflozin premixes
|
BR112018072401A2
(pt)
|
2016-06-10 |
2019-02-19 |
Boehringer Ingelheim International Gmbh |
combinações de linagliptina e metformina
|
WO2018002673A1
(en)
|
2016-07-01 |
2018-01-04 |
N4 Pharma Uk Limited |
Novel formulations of angiotensin ii receptor antagonists
|
US11433086B2
(en)
|
2016-08-08 |
2022-09-06 |
Glycomimetics, Inc. |
Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
|
US11427555B2
(en)
*
|
2016-08-09 |
2022-08-30 |
Laurus Labs Limited |
Processes for preparation of dapagliflozin or its solvates or co-crystals thereof
|
WO2018029264A1
(en)
|
2016-08-10 |
2018-02-15 |
Amneal Pharmaceuticals Company Gmbh |
Process for preparation of dapagliflozin and intermediates thereof
|
KR20240046288A
(ko)
|
2016-10-07 |
2024-04-08 |
글리코미메틱스, 인크. |
매우 강력한 다량체성 e-셀렉틴 길항물질
|
AU2017344882A1
(en)
|
2016-10-19 |
2019-03-28 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an SSAO/VAP-1 inhibitor and a SGLT2 inhibitor, uses thereof
|
KR20180058510A
(ko)
|
2016-11-24 |
2018-06-01 |
한미약품 주식회사 |
다파글리플로진 l-프롤린을 포함하는 약제학적 제제
|
CN108218928B
(zh)
*
|
2016-12-13 |
2020-06-30 |
华润双鹤药业股份有限公司 |
葡萄糖苷的二环衍生物及其制备方法和用途
|
WO2018142422A1
(en)
*
|
2017-02-02 |
2018-08-09 |
Indoco Remedies Limited |
Process for the preparation of dapagliflozin
|
JP7272956B2
(ja)
|
2017-03-15 |
2023-05-12 |
グリコミメティクス, インコーポレイテッド |
E-セレクチンアンタゴニストとしてのガラクトピラノシル-シクロヘキシル誘導体
|
US11020412B2
(en)
|
2017-03-16 |
2021-06-01 |
Inventia Healthcare Limited |
Pharmaceutical composition comprising dapagliflozin
|
CA3058806A1
(en)
|
2017-04-03 |
2018-10-11 |
Coherus Biosciences Inc. |
Ppar.gamma. agonist for treatment of progressive supranuclear palsy
|
WO2018207111A1
(en)
|
2017-05-09 |
2018-11-15 |
Piramal Enterprises Limited |
A process for the preparation of sglt2 inhibitors and intermediates thereof
|
AR112015A1
(es)
|
2017-06-09 |
2019-09-11 |
Novo Nordisk As |
Composiciones sólidas para administración oral
|
KR101943382B1
(ko)
|
2017-09-19 |
2019-01-29 |
오토텔릭바이오 주식회사 |
Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
|
US11712446B2
(en)
|
2017-11-30 |
2023-08-01 |
Glycomimetics, Inc. |
Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
|
KR20200104889A
(ko)
|
2017-12-29 |
2020-09-04 |
글리코미메틱스, 인크. |
E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제
|
CA3091454A1
(en)
|
2018-03-05 |
2019-09-12 |
Glycomimetics, Inc. |
Methods for treating acute myeloid leukemia and related conditions
|
JP2021520394A
(ja)
|
2018-04-17 |
2021-08-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物、処置方法及びその使用
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
WO2020001812A1
(en)
|
2018-06-25 |
2020-01-02 |
Pharmathen S.A. |
A novel process for the preparation of sglt-2 inhibitors
|
MA53175A
(fr)
*
|
2018-07-19 |
2021-05-26 |
Astrazeneca Ab |
Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
KR102131359B1
(ko)
|
2018-09-07 |
2020-07-07 |
오토텔릭바이오 주식회사 |
안정성이 향상된 의약 조성물
|
CN109705075B
(zh)
*
|
2018-12-13 |
2022-12-23 |
苏中药业集团股份有限公司 |
一种达格列净的纯化方法
|
US11845771B2
(en)
|
2018-12-27 |
2023-12-19 |
Glycomimetics, Inc. |
Heterobifunctional inhibitors of E-selectin and galectin-3
|
BR112020008705A2
(pt)
|
2019-08-30 |
2022-03-22 |
Astrazeneca Ab |
Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
|
CN114727624A
(zh)
|
2019-11-28 |
2022-07-08 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂在非人哺乳动物的停奶中的用途
|
MX2022010090A
(es)
|
2020-02-17 |
2022-09-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos.
|
CA3169665A1
(en)
|
2020-02-21 |
2021-08-26 |
Zaklady Farmaceutyczne Polpharma S.A. |
Pharmaceutical composition comprising dapagliflozin
|
WO2021176096A1
(en)
|
2020-03-05 |
2021-09-10 |
Krka, D.D., Novo Mesto |
Pharmaceutical composition comprising sglt2 inhibitor
|
BR112022017189A2
(pt)
|
2020-03-06 |
2022-10-18 |
Vertex Pharma |
Métodos de tratamento de glomeruloesclerose segmentar focal dependente de apol-1
|
CA3180674A1
(en)
|
2020-04-22 |
2021-10-28 |
Bayer Aktiengesellschaft |
Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
|
WO2021219691A1
(en)
|
2020-04-29 |
2021-11-04 |
Astrazeneca Ab |
Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
|
CN115867538A
(zh)
|
2020-06-05 |
2023-03-28 |
新梅斯托克公司 |
高纯的无定形达格列净的制备
|
WO2021260617A1
(en)
*
|
2020-06-25 |
2021-12-30 |
Hikal Limited |
An improved process for preparation of dapagliflozin propanediol monohydrate
|
CA3188345A1
(en)
|
2020-07-10 |
2022-01-13 |
Astrazeneca Ab |
Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
|
US20220023252A1
(en)
|
2020-07-27 |
2022-01-27 |
Astrazeneca Ab |
Methods of treating chronic kidney disease with dapagliflozin
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
WO2022067724A1
(zh)
|
2020-09-30 |
2022-04-07 |
北京睿创康泰医药研究院有限公司 |
一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用
|
TR202019590A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür formülasyonlarina yöneli̇k bi̇r proses
|
WO2022119543A1
(en)
|
2020-12-03 |
2022-06-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
A process for tablet formulations comprising amorphous dapagliflozin and metformin hydrochloride
|
TR202019592A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Amorf dapagliflozinin katı farmasötik formülasyonları
|
TR202019589A2
(tr)
|
2020-12-03 |
2022-06-21 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Dapagli̇flozi̇n ve metformi̇n hi̇droklorür i̇çeren fi̇lm kapli tablet formülasyonu
|
AU2022251165A1
(en)
|
2021-04-01 |
2023-11-09 |
Astrazeneca Uk Limited |
Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
|
EP4079296A1
(en)
|
2021-04-21 |
2022-10-26 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
CN117715640A
(zh)
|
2021-07-28 |
2024-03-15 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物,特别是犬科动物中预防和/或治疗心脏疾病的用途
|
EP4376830A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
CN113773194B
(zh)
|
2021-08-16 |
2023-05-02 |
浙江奥翔药业股份有限公司 |
作为降糖药合成原料的5-溴-2-氯-苯甲酸的制备方法
|
WO2023129595A1
(en)
|
2021-12-30 |
2023-07-06 |
Newamsterdam Pharma B.V. |
Obicetrapib and sglt2 inhibitor combination
|
EP4212150A1
(en)
|
2022-01-13 |
2023-07-19 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A bilayer tablet composition comprising amorphous dapagliflozin and metformin
|
WO2023144722A1
(en)
|
2022-01-26 |
2023-08-03 |
Astrazeneca Ab |
Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
|
TW202412756A
(zh)
|
2022-05-25 |
2024-04-01 |
德商百靈佳殷格翰維美迪加股份有限公司 |
包含sglt-2抑制劑之水性醫藥組合物
|
WO2023237512A1
(en)
|
2022-06-07 |
2023-12-14 |
Astrazeneca Ab |
Combinations of rxfp1 modulators and sglt2 inhibitors
|
KR102490653B1
(ko)
*
|
2022-08-03 |
2023-01-20 |
진양제약주식회사 |
다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
|
KR20240028315A
(ko)
|
2022-08-24 |
2024-03-05 |
주식회사 제뉴원사이언스 |
다파글리플로진, 시타글립틴, 및 메트포르민을 함유하는 복합 제제
|
WO2024166009A1
(en)
|
2023-02-08 |
2024-08-15 |
Astrazeneca Ab |
Combination of zibotentan and dapagliflozin for the treatment of high proteinuria chronic kidney disease
|